Show simple item record

dc.contributor.authorSchiavone, Fen_US
dc.contributor.authorBathia, Ren_US
dc.contributor.authorLetchemanan, Ken_US
dc.contributor.authorMasters, Len_US
dc.contributor.authorAmos, Cen_US
dc.contributor.authorBara, Aen_US
dc.contributor.authorBrown, Len_US
dc.contributor.authorGilson, Cen_US
dc.contributor.authorPugh, Cen_US
dc.contributor.authorAtako, Nen_US
dc.contributor.authorHudson, Fen_US
dc.contributor.authorParmar, Men_US
dc.contributor.authorLangley, Ren_US
dc.contributor.authorKaplan, RSen_US
dc.contributor.authorParker, Cen_US
dc.contributor.authorAttard, Gen_US
dc.contributor.authorClarke, NWen_US
dc.contributor.authorGillessen, Sen_US
dc.contributor.authorJames, NDen_US
dc.contributor.authorMaughan, Ten_US
dc.contributor.authorSydes, MRen_US
dc.contributor.authorpast and present members of the STAMPEDE and FOCUS4 Trial Management Groupen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-06-24T08:53:35Z
dc.date.issued2019-05-29en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31138317en_US
dc.identifier10.1186/s13063-019-3216-8en_US
dc.identifier.citationTrials, 2019, 20 (1), pp. 264 - ?en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3269
dc.identifier.eissn1745-6215en_US
dc.identifier.doi10.1186/s13063-019-3216-8en_US
dc.description.abstractBACKGROUND: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes. METHODS: We evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation. RESULTS: Specific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials. Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges. CONCLUSIONS: Understanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective. TRIAL REGISTRATION: FOCUS4: ISRCTN Registry, ISRCTN90061546 . Registered on 16 October 2013. STAMPEDE: ISRCTN Registry, ISRCTN78818544 . Registered on 2 February 2004.en_US
dc.format.extent264 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAdaptive trialsen_US
dc.subjectMulti-arm multi stageen_US
dc.subjectPlatformen_US
dc.subjectProtocolen_US
dc.subjectTrial conducten_US
dc.subjectTrial managementen_US
dc.titleThis is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.en_US
dc.typeJournal Article
dcterms.dateAccepted2019-01-19en_US
rioxxterms.versionofrecord10.1186/s13063-019-3216-8en_US
rioxxterms.licenseref.startdate2019-05-29en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfTrialsen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished onlineen_US
pubs.volume20en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorParker, Chrisen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/